Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

NCT03863587 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
24
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated prematurely due to the difficulty in recruiting participants caused by the COVID-19 pandemic.

Conditions

Interventions

Sponsor

Shanghai Henlius Biotech